The early stages of multiple sclerosis: new targets for the development of combinational drug therapies

Abstract

This chapter examines the bacterial triggers of rheumatoid arthritis and how they may induce self-reactive antibody production. In so doing, this report highlights some targets for drug treatments aimed at blocking the early phases of multiple sclerosis before the more serious later phase events occur.